No paralogue variants have been mapped to residue 1728 for RYR1.
RYR1 | EDAHLPGPLRAGYYDLLISIHLESACRSRR>S<MLSEYIVPLTPETRAITLFPPGRSTENGHP | 1758 |
RYR2 | ENKYMPGLLRAGYYDLLIDIHLSSYATARL>M<MNNEYIVPMTEETKSITLFPD------ENK | 1744 |
RYR3 | DNKYLPGLLRSGFYDLLISIHLASAKERKL>M<MKNEYIIPITSTTRNIRLFPD------ESK | 1648 |
cons | > < |
Protein | CDS | Disease Classification | Disease | dbSNP links | Effect Prediction |
---|---|---|---|---|---|
p.S1728P | c.5182T>C | Other Myopathy | rs193922780 | SIFT: Polyphen: | |
Reports | Other Myopathy | Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. Anesthesiology. 2005 102(3):515-21. 15731587 | |||
p.S1728F | c.5183C>T | Other Myopathy | rs193922781 | SIFT: Polyphen: | |
Reports | Other Myopathy | Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat. 2006 27(10):977-89. 16917943 | |||
Other Myopathy | Genetic variation in RYR1 and malignant hyperthermia phenotypes. Br J Anaesth. 2009 103(4):538-48. doi: 10.1093/bja/aep204. 19648156 | ||||
Other Myopathy | Using exome data to identify malignant hyperthermia susceptibility mutations. Anesthesiology. 2013 119(5):1043-53. doi: 10.1097/ALN.0b013e3182a8a8e7. 24195946 | ||||
Unknown | Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res. 2015 25(3):305-15. doi: 10.1101/gr.183483.114. 25637381 |